Skip to main content

Advertisement

SpringerLink
Log in

Endogenous testosterone as a predictor of prostate growing disorders in the aging male

  • Urology - Original Paper
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Objective

To investigate the associations of endogenous testosterone with prostate growing disorders (PGD) including benign prostatic hyperplasia (BPH) and prostate cancer (PCA).

Methods

The study population was composed by 1176 cases including 371 BPH subjects (31.5%) without cancer who underwent prostate transurethral resection from January 2017 to November 2019 and 805 patients (68.5%) with PCA who underwent surgery from November 2014 to December 2019. The association of endogenous testosterone, which was measured before surgery, with the risk of PGD was evaluated by statistical methods.

Results

In the study population, endogenous testosterone levels were significantly lower in PCA cases compared to BPH patients who were older with larger prostates but lower prostate-specific antigen (PSA) levels. On multivariate analysis, the risk of PCA decreased by endogenous testosterone (odds ratio, OR = 0.957; 95% CI 0.930–0.984; p = 0.002) as by age (OR = 0.955; 95% CI  0.933–0.984; p < 0,0001) and prostate volume (OR = 0.930; 95% CI 0.919–0.940; p < 0.0001) but increased by PSA (OR = 1.652; 95% CI 1.542–1.769; p < 0.0001). On multivariate linear regression analysis, endogenous testosterone inversely associated with body mass index (BMI) (regression coefficient, b =  – 0.279; p = 0.002) and PCA (b =  – 2.935; p < 0.0001).

Conclusions

In the aging male, endogenous testosterone independently predicted malignant prostate disorders, which associated with decreased hormone levels along BMI categories. Endogenous testosterone is a further marker for evaluating prostate growing disorders in clinical practice; however, controlled studies are required.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Gravas S et al. (2020) EAU Guidelines on Management of Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO) 2020, in European Association of Urology Guidelines. 2020 Edition. 2020, European Association of Urology Guidelines Office: Arnhem, The Netherlands

  2. Mottet N et al. (2020) EAU - ESTRO - ESUR - SIOG Guidelines on Prostate Cancer 2020, in European Association of Urology Guidelines. 2020 Edition. 2020, European Association of Urology Guidelines Office: Arnhem, The Netherlands

  3. Mohler JL et al (2019) Prostate cancer, version 22019, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw 17(5):479–505

    Article  CAS  Google Scholar 

  4. Klap J, Schmid M, Loughlin KR (2015) The relationship between total testosterone levels and prostate cancer: a review of the continuing controversy. J Urol 193(2):403–414

    Article  CAS  PubMed  Google Scholar 

  5. Lopez DS et al (2017) Endogenous and exogenous testosterone and prostate cancer: decreased-, increased-or null-risk? Trans Androl Urol 6(3):566

    Article  Google Scholar 

  6. Loughlin KR (2016) The testosterone conundrum: the putative relationship between testosterone levels and prostate cancer in Urologic Oncology: Seminars and Original Investigations. Elsevier, The Netherlands

    Google Scholar 

  7. Menon M, Tewari A, Peabody J (2003) Vattikuti Institute prostatectomy: technique. J Urol 169(6):2289–2292

    Article  PubMed  Google Scholar 

  8. Walsh PC (1986) Campbell's urology. Vol. 2 WB Saunders Co

  9. Porcaro AB et al (2016) Low-risk prostate cancer and tumor upgrading in the surgical specimen: analysis of clinical factors predicting tumor upgrading in a contemporary series of patients who were evaluated according to the modified Gleason score grading system. Curr Urol 10(3):118–125

    Article  CAS  Google Scholar 

  10. Sebben M et al. (2020) The impact of extended pelvic lymph node dissection on the risk of hospital readmission within 180 days after robot assisted radical prostatectomy. World J Urol 1–11

  11. Epstein JI et al. (2016) The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol 40(2): 244–252

  12. Porcaro AB et al (2019) Positive association between basal total testosterone circulating levels and tumor grade groups at the time of diagnosis of prostate cancer. Urol Int 103(4):400–407

    Article  CAS  PubMed  Google Scholar 

  13. Tafuri A et al (2020) Predictive Factors of the Risk of Long-Term Hospital Readmission after Primary Prostate Surgery at a Single Tertiary Referral Center: Preliminary Report. Urol Int 104(5–6):465–475

    Article  PubMed  Google Scholar 

  14. Tafuri A et al. (2020) Endogenous testosterone mirrors prostate cancer aggressiveness: correlation between basal testosterone serum levels and prostate cancer European Urology Association clinical risk classes in a large cohort of Caucasian patients. Int Urol Nephrol 1–9

  15. Shaneyfelt T et al (2000) Hormonal predictors of prostate cancer: a meta-analysis. J Clin Oncol 18(4):847–847

    Article  CAS  PubMed  Google Scholar 

  16. Rannikko S, Adlercreutz H (1983) Plasma estradiol, free testosterone, sex hormone binding globulin binding capacity, and prolactin in benign prostatic hyperplasia and prostatic cancer. Prostate 4(3):223–229

    Article  CAS  PubMed  Google Scholar 

  17. Kumar VL et al (1990) Androgen, estrogen, and progesterone receptor contents and serum hormone profiles in patients with benign hypertrophy and carcinoma of the prostate. J Surg Oncol 44(2):122–128

    Article  CAS  PubMed  Google Scholar 

  18. Karamanolakis D et al. (2006) Serum testosterone: a potentially adjunct screening test for the assessment of the risk of prostate cancer among men with modestly elevated PSA values (≥ 3.0 and< 10.0 ng/ml). Anticancer Res 26(4B): 3159–3166

  19. Sofikerim M et al (2007) Hormonal predictors of prostate cancer. Urol Int 79(1):13–18

    Article  CAS  PubMed  Google Scholar 

  20. Mearini L et al (2008) Testosterone levels in benign prostatic hypertrophy and prostate cancer. Urol Int 80(2):134–140

    Article  CAS  PubMed  Google Scholar 

  21. Mearini L et al (2013) Low serum testosterone levels are predictive of prostate cancer. World J Urol 31(2):247–252

    Article  CAS  PubMed  Google Scholar 

  22. Usoro AJ et al (2015) Serum testosterone, 17β-Estradiol and PSA levels in subjects with prostate disorders. Indian J Clin Biochem 30(1):59–65

    Article  CAS  PubMed  Google Scholar 

  23. Grosman H et al (2016) Complex relationship between sex hormones, insulin resistance and leptin in men with and without prostatic disease. Aging Male 19(1):40–45

    Article  CAS  PubMed  Google Scholar 

  24. Miyoshi Y et al (2017) High serum dihydrotestosterone examined by ultrasensitive LC-MS/MS as a predictor of benign prostatic hyperplasia or Gleason score 6 cancer in men with prostate-specific antigen levels of 3–10 ng/mL. Andrology 5(2):262–267

    Article  CAS  PubMed  Google Scholar 

  25. De Nunzio C et al (2012) The correlation between metabolic syndrome and prostatic diseases. Eur Urol 61(3):560–570

    Article  PubMed  Google Scholar 

  26. Wu FC et al (2008) Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. J Clin Endocrinol Metab 93(7):2737–2745

    Article  CAS  PubMed  Google Scholar 

  27. De Nunzio C et al (2013) Abdominal obesity as risk factor for prostate cancer diagnosis and high grade disease: a prospective multicenter Italian cohort study in Urologic Oncology: Seminars and Original Investigations. Elsevier, The Netherland

    Google Scholar 

  28. Duarte M et al (2018) (2018) Clinical and metabolic implications of obesity in prostate cancer: is testosterone a missing link? Aging Male 10(1080/13685538):1519695

    Google Scholar 

  29. Porcaro AB et al (2020) High body mass index predicts multiple prostate cancer lymph node metastases after radical prostatectomy and extended pelvic lymph node dissection. Asian J Androl 22(3):323

    Article  CAS  PubMed  Google Scholar 

  30. Tafuri A et al. (2020) Obesity strongly predicts clinically undetected multiple lymph node metastases in intermediate-and high-risk prostate cancer patients who underwent robot assisted radical prostatectomy and extended lymph node dissection. Int Urol Nephrol 1–9

  31. Porcaro AB et al (2019) Low Preoperative Prolactin Levels Predict Non-Organ Confined Prostate Cancer in Clinically Localized Disease. Urol Int 103(4):391–399

    Article  CAS  PubMed  Google Scholar 

  32. Porcaro AB et al (2011) Investigative clinical study on prostate cancer Part V: Luteinizing hormone and the pituitary-testicular-prostate axis at the time of initial diagnosis and subsequent cluster selection of the patient population. Anticancer Res 31(3):1071–1078

    CAS  PubMed  Google Scholar 

  33. Porcaro AB et al (2013) Follicle-stimulating hormone and the pituitary-testicular-prostate axis at the time of initial diagnosis of prostate cancer and subsequent cluster selection of the patient population undergoing standard radical prostatectomy. Urol Int 90(1):45–55

    Article  CAS  PubMed  Google Scholar 

  34. Morgentaler A, Traish AM (2009) Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol 55(2):310–321

    Article  PubMed  Google Scholar 

  35. Tafuri A et al. (2020) Serum testosterone and obesity in prostate cancer biology: a call for health promotion in the ageing male. Aging Clin Experim Res 1–3

  36. Brambilla DJ et al (2009) The effect of diurnal variation on clinical measurement of serum testosterone and other sex hormone levels in men. J Clin Endocrinol Metabol 94(3):907–913

    Article  CAS  Google Scholar 

Download references

Author information

Author notes

  1. Antonio Benito Porcaro, Nelia Amigoni, Alessandro Tafuri these authors have contributed equally to this manuscript.

Authors and Affiliations

  1. Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Piazzale Aristide Stefani 1, 37126, Verona, Italy

    Antonio Benito Porcaro, Nelia Amigoni, Alessandro Tafuri, Riccardo Rizzetto, Leone Tiso, Clara Cerrato, Vincenzo Lacola, Stefano Zecchini Antoniolli, Alessandra Gozzo, Katia Odorizzi, Filippo Migliorini, Walter Artibani, Maria Angela Cerruto, Salvatore Siracusano & Alessandro Antonelli

  2. Departement of Neuroscience, Imaging and Clinical Sciences, “G. D’Annunzio” University, Chieti, Italy

    Alessandro Tafuri

  3. Institute of Urology and Catherine and Joseph Aresty Department of Urology, USC, University of Southern California (USC), Keck School of Medicine, Los Angeles, CA, USA

    Aliasger Shakir

  4. Department of Pathology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy

    Matteo Brunelli

Authors
  1. Antonio Benito Porcaro
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nelia Amigoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alessandro Tafuri
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Riccardo Rizzetto
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Aliasger Shakir
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Leone Tiso
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Clara Cerrato
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Vincenzo Lacola
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Stefano Zecchini Antoniolli
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Alessandra Gozzo
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Katia Odorizzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Matteo Brunelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Filippo Migliorini
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Walter Artibani
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Maria Angela Cerruto
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Salvatore Siracusano
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Alessandro Antonelli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Antonio Benito Porcaro.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Porcaro, A.B., Amigoni, N., Tafuri, A. et al. Endogenous testosterone as a predictor of prostate growing disorders in the aging male. Int Urol Nephrol 53, 843–854 (2021). https://doi.org/10.1007/s11255-020-02747-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-020-02747-w

Keywords

Search

Navigation